{"id":484122,"date":"2021-04-29T07:33:27","date_gmt":"2021-04-29T11:33:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/"},"modified":"2021-04-29T07:33:27","modified_gmt":"2021-04-29T11:33:27","slug":"intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/","title":{"rendered":"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  29, 2021  (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both <em>in vivo<\/em> and <em>ex vivo<\/em>, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T.<\/p>\n<p>To join the call:<\/p>\n<ul type=\"disc\">\n<li>U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call.<\/li>\n<li>All participants should ask to be connected to the Intellia Therapeutics conference call.<\/li>\n<\/ul>\n<p>A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j5UYgxLbacKRC5N5sWx11Ui0vssN82LImEilhqwBHqJjxyVAfef7AEiRGWdB5znpyfPOwTRGwYp2mMR6QPqXovo2XykC5DwwMpE7bD4qENZWH8uXspdPSsHTVIxW907FN0a_dGxLXp74VDjT-uuJpIwzbm3oOfBN7IXYRiVFGdeBGzfBc9G4ADlqhoxAWeF0\" rel=\"nofollow noopener\" target=\"_blank\">www.intelliatx.com,<\/a> beginning on May 6 at 12 p.m. E.T.<\/p>\n<p>\n        <strong>About Intellia Therapeutics<\/strong><br \/>\n        <br \/>Intellia Therapeutics\u00a0is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR\/Cas9 system. Intellia believes the CRISPR\/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and\/or correct disease-associated genes in the human body with a single administration, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia\u2019s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR\/Cas9 technology and create new classes of therapeutic products. Learn more about\u00a0Intellia and CRISPR\/Cas9 at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=28QMa4sCiOIojyGco_pI4pMvk3Khn5GLU3MR_IKme9KLNM7eOudDxc6dHNmX2L7E9kP7L5S5oAzpPqgca12kBtc9aOpCoGHHEzZiCn2R1zFsBJl3mCqSvArQybUsJgIlgisWEjg1jL1GPfPeKIwEMjkHDrvEdr959CGKa5Fq6NtqvEtmEiCtOy5u_2O3rdKJ\" rel=\"nofollow noopener\" target=\"_blank\">intelliatx.com.<\/a> Follow us on Twitter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UpvnwBDCicdu0mjtOq5MHnJsp4Trcx0HLye3-hHGDM_IL035C2RiuCif8CoFkMoCdbwajDfhE80h9crEqKg4WsLYCCEj6YU0Vidj6MiCxFY=\" rel=\"nofollow noopener\" target=\"_blank\">@intelliatweets<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Intellia Contacts:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<br \/><\/strong>Lina Li<br \/>Director<br \/>Investor Relations<br \/>+1-857-706-1612<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ErsnTXIghAtJlM0ZessEHFoRvBQA12e1zdXu8YzedA8olLKxM1URMGve--X5j80pnkxjK2_gep_0kSlTMbsGvK4JIwRmCey1JtU2O0KIlEo=\" rel=\"nofollow noopener\" target=\"_blank\">lina.li@intelliatx.com<\/a><\/p>\n<p>\n        <strong>Media:<br \/><\/strong>Julie Ferguson<br \/>Interim Head of External Affairs &amp; Communications<br \/>+1-312-385-0098<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3UrLcMHYfAL9Sl90O1BJBOVRO9SKzB9NPhQttEnjlMW0IXIGOPcq6c5qOiYU56Gh4Y8Xes_ghRfxf-00rthWQ73g3wUIgF1xZ7ePyxL-MSP3nNwSi6j9rFaT1ftrcLXZ\" rel=\"nofollow noopener\" target=\"_blank\">julie.ferguson@intelliatx.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/bdfb0219-b44c-4300-b7e0-3f800e9d4fed\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at www.intelliatx.com, beginning on May 6 at 12 p.m. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-484122","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at www.intelliatx.com, beginning on May 6 at 12 p.m. &hellip; Continue reading &quot;Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-29T11:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates\",\"datePublished\":\"2021-04-29T11:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/\"},\"wordCount\":297,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/\",\"name\":\"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=\",\"datePublished\":\"2021-04-29T11:33:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at www.intelliatx.com, beginning on May 6 at 12 p.m. &hellip; Continue reading \"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-29T11:33:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates","datePublished":"2021-04-29T11:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/"},"wordCount":297,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/","name":"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=","datePublished":"2021-04-29T11:33:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNTcyMyM0MTQ0NzM0IzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-first-quarter-2021-earnings-and-company-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics to Hold Conference Call\u00a0to Discuss First Quarter 2021 Earnings\u00a0and Company Updates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=484122"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484122\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=484122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=484122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=484122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}